Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal versus subcutaneous Imojev vaccination for Japanese encephalitis prevention
ACTRN12623000214639Phase 3Completed
- Sponsor
- Sydney Children's Hospitals Network
- Start
- Jan 2023
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of japanese encephalitis chimeric virus vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Sydney Children's Hospitals Network. Primary endpoint: Seroconversion at Day 28-35. Started Jan 2023; status: completed.
02
Drugs
japanese encephalitis chimeric virus vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on ACTRN12623000214639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000214639.